FDA Informs Arrowhead of Partial Clinical Hold for Hepatitis B Drug

Arrowhead Research Corp. said Monday that U.S. regulators informed the company of a partial clinical hold for a potential hepatitis B treatment.



from WSJ.com: US Business http://ift.tt/1DAt86b

via IFTTT